These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 4293687)

  • 21. Investigation of some possibilities of producing type 3 vaccine poliovirus with greater genetic stability. I. Preliminary experiments with passage variants.
    Elbert LB; Chumakov MP; Krutyanskaya GL; Ralph NM; Tyufanov AV
    Acta Virol; 1968 May; 12(3):193-202. PubMed ID: 4385148
    [No Abstract]   [Full Text] [Related]  

  • 22. Poliovirus antibody status and the response to trivalent oral poliovirus vaccine in Norwegian school children.
    Orstavik I; Flugsrud LB; Lahelle O
    Acta Paediatr Scand; 1968 Sep; 57(5):405-8. PubMed ID: 4974044
    [No Abstract]   [Full Text] [Related]  

  • 23. [Antibody status one year after the completion of a cycle of immunization with Sabin's oral poliomyelitis vaccine].
    Assumma M; Russo V; Alemanno A
    Arch Ital Sci Med Trop Parassitol; 1967; 48(7):175-86. PubMed ID: 5615073
    [No Abstract]   [Full Text] [Related]  

  • 24. [Behavior of poliovirus neutralizing antibodies in 108 subjects vaccinated with the Sabin vaccine].
    Andreoni G; Curatolo D; Cervini E; Rocchi G; Velli V
    G Mal Infett Parassit; 1966 Oct; 18(10):653-7. PubMed ID: 5997193
    [No Abstract]   [Full Text] [Related]  

  • 25. Virology. Poliomyelitis eradication--a dangerous endgame.
    Nathanson N; Fine P
    Science; 2002 Apr; 296(5566):269-70. PubMed ID: 11951020
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of different immunisation schedules on the excretion and reversion of oral poliovaccine strains.
    Minor PD; Dunn G; Ramsay ME; Brown D
    J Med Virol; 2005 Jan; 75(1):153-60. PubMed ID: 15543587
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurologic complications associated with oral poliovirus vaccine and genomic variability of the vaccine strains after multiplication in humans.
    Friedrich F
    Acta Virol; 1998 Jun; 42(3):187-94. PubMed ID: 9842449
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studies on new attenuated strains of type III live poliomyelitis vaccine. II. Field trials of Zhong III2 virus.
    Chin Med J (Engl); 1980 Sep; 93(9):591-8. PubMed ID: 6253237
    [No Abstract]   [Full Text] [Related]  

  • 29. [On the problem of revaccination against poliomyelitis. Results of a reinfection experiment using the poliovirus type 1, strain "LSc, 2ab (Sabin)". 4 and half years following original vaccination].
    Kuwert E; Posch J; Lagarie G
    Med Klin; 1968 May; 63(18):701-7. PubMed ID: 4305218
    [No Abstract]   [Full Text] [Related]  

  • 30. Neurovirulence test for oral live poliovaccines using poliovirus-sensitive transgenic mice.
    Abe S; Ota Y; Koike S; Kurata T; Horie H; Nomura T; Hashizume S; Nomoto A
    Virology; 1995 Feb; 206(2):1075-83. PubMed ID: 7856082
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of a newly identified attenuating mutation in Sabin 3 oral poliovirus vaccine.
    Mento SJ; Weeks-Levy C; Tatem JM; Gorgacz EJ; Waterfield WF
    Dev Biol Stand; 1993; 78():93-9; discussion 99-100. PubMed ID: 8388835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New assays for the quality control of live oral poliovirus vaccine.
    Furesz J; Levenbook I
    Acta Microbiol Immunol Hung; 1998; 45(3-4):391-9. PubMed ID: 9873944
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurovirulence testing of oral poliovaccine in the rhesus monkey.
    Arya SC
    Indian J Pathol Microbiol; 1976 Jul; 19(3):185-94. PubMed ID: 186408
    [No Abstract]   [Full Text] [Related]  

  • 34. [Research on the administration of Mexaform in the course of anti-poliomyelitis vaccination with Sabin's attenuated virus].
    Crovari P; Bori D
    Minerva Med; 1967 Apr; 58(33):1497-502. PubMed ID: 6026631
    [No Abstract]   [Full Text] [Related]  

  • 35. [Autohistoradiographic investigations of the lymphatic and splenic localization of poliovirus, type 3, attenuated according to Sabin's method and labeled with I-131. (Experimental research)].
    Nigro N; Mussa GC; Mussa A
    Minerva Pediatr; 1966 Feb; 18(4):149-52. PubMed ID: 4286574
    [No Abstract]   [Full Text] [Related]  

  • 36. Oral poliovirus vaccine type 3 from a patient with transverse myelitis is neurovirulent in a transgenic mouse model.
    Thorley B; Kelly H; Nishimura Y; Yoon YK; Brussen KA; Roberts J; Shimizu H
    J Clin Virol; 2009 Apr; 44(4):268-71. PubMed ID: 19269246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shedding of sabin poliovirus Type 3 containing the nucleotide 472 uracil-to-cytosine point mutation after administration of oral poliovirus vaccine.
    Martinez CV; Old MO; Kwock DK; Khan SS; Garcia JJ; Chan CS; Webster R; Falkovitz-Halpern MS; Maldonado YA
    J Infect Dis; 2004 Jul; 190(2):409-16. PubMed ID: 15216480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A poliovirus-susceptible transgenic mouse model as a possible replacement for the monkey neurovirulence test of oral poliovirus vaccine.
    Dragunsky E; Taffs R; Chernokhvostova Y; Nomura T; Hioki K; Gardner D; Norwood L; Levenbook I
    Biologicals; 1996 Jun; 24(2):77-86. PubMed ID: 8889053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential sensitivity of virulent and attenuated strains of type 1 poliovirus to polyethylene glycol as a possible new genetic marker.
    Lokteva VF; Chumakov MP; Zhevandrova VI; Shekoyan LA
    Arch Gesamte Virusforsch; 1973; 41(3):155-9. PubMed ID: 4353792
    [No Abstract]   [Full Text] [Related]  

  • 40. Oral poliovaccine: will it help eradicate polio or cause the next epidemic?
    Shulman LM; Manor Y; Sofer D; Swartz T; Mendelson E
    Isr Med Assoc J; 2006 May; 8(5):312-5. PubMed ID: 16805227
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.